Get notified of page updates

A Study of the PARP Inhibitor Saruparib Added to Standard Treatment for High Risk BRCA-Positive Prostate Cancer (EvoPAR PR02)

Treatment

Phase 3 treatment study for BRCA-positive high-risk prostate cancer

Clinicaltrials.gov identifier:
NCT06952803

Study Contact Information:

AstraZeneca Clinical Study Information Center
📞 1‑877‑240‑9479
📧 [email protected]

PRINTER FRIENDLY PAGE
Overview
Who Can Join
Details
Contact
Locations
Glossary on
off

About the Study

This study is testing a new medication called saruparib (AZD5305) to see if it can help people with cancer that is high risk for getting worse or spreading to other parts of the body. Saruparib is a type of known as a . The study is open to people with a or mutation. The goal of this study is to find out if adding saruparib after radiation treatment can lower the chances of the cancer coming back or spreading.

This Study is Open To:

You may be able to join if you have all of the following:

  • Are 18 or older
  • Have high‑risk or very high‑risk cancer that:
    • Has not spread outside the pelvis, or
    • Came back after surgery (biochemical recurrence)
  • Have a confirmed or mutation found on tumor testing
  • Have had or are currently having radiation therapy
  • Are receiving hormone therapy (ADT)
  • Are able to carry out most daily activities

This Study is NOT Open To:

You cannot join if you:

  • Have already received chemotherapy or a
  • Have certain serious medical conditions
  • Have another active cancer (with some exceptions)

What the Study Involves

Everyone in the study will receive standard treatment for cancer, including hormone therapy. Some participants may also receive plus prednisone, depending on their cancer features.

Participants are then randomly assigned to receive either:

  • Saruparib (the study drug), or
  • A (a pill with no active medicine)

Neither the participant nor the study doctor will know which treatment is being given. Treatment with saruparib or can last up to 2 years. Participants will be followed after treatment is complete.

Researchers will measure how long participants live without the cancer returning or spreading. This is called "metastasis-free survival." They will also track how long study participants live overall, as well as any side effects of the medication(s).

Study Contact Information:

AstraZeneca Clinical Study Information Center
📞 1‑877‑240‑9479
📧 [email protected]

Locations:

Arizona

City: Phoenix RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

California

City: La Jolla RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

City: Los Angeles RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Colorado

City: Lakewood RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Florida

City: Jacksonville RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

City: Tampa RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Georgia

City: Newnan RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Maryland

City: Bethesda RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

City: Towson RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Minnesota

City: Rochester RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

New Jersey

City: Hackensack RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

City: Voorhees Township RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Ohio

City: Columbus RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

South Carolina

City: Myrtle Beach RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Tennessee

City: Nashville RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Texas

City: Austin RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

City: Houston RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

City: San Antonio RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Other Countries

Country: Australia
City: Murdoch RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: South Brisbane RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: St Leonards RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: Waratah RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Australia
City: Woolloongabba RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Belgium
City: Kortrijk RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Belgium
City: Roeselare RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Brazil
City: Pelotas RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Brazil
City: Salvador RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Brazil
City: São Paulo RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: China
City: Nanchang RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: China
City: Sichuan RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: France
City: Montpellier RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: France
City: Paris RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: France
City: Suresnes RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: France
City: Tours RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: France
City: Vandœuvre-lès-Nancy RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: India
City: Nagpur RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Bunkyō City RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Fukuoka RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Kamakura-shi RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Kawagoe-shi RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Kisarazu-shi RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Maebashi RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Japan
City: Sagamihara-shi RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Netherlands
City: Hilversum RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Busan RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Daegu RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Goyang-si RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Seoul RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Seoul RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Seoul RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Seoul RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Seoul RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: South Korea
City: Seoul RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Taiwan
City: Taipei RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Taiwan
City: Taipei RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Taiwan
City: Taoyuan District RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Thailand
City: Khon Kaen RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Thailand
City: Muang RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Thailand
City: Pathum Thani RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: Thailand
City: Songkhla RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: United Kingdom
City: Aberdeen RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: United Kingdom
City: London RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Country: United Kingdom
City: Plymouth RECRUITING
Facility: Research Site
Contact Info:
No contact info provided

Treatment

Phase 3 treatment study for BRCA-positive high-risk prostate cancer

Clinicaltrials.gov identifier:
NCT06952803

Study Contact Information:

AstraZeneca Clinical Study Information Center
📞 1‑877‑240‑9479
📧 [email protected]

PRINTER FRIENDLY PAGE